REG - BATM Advanced Comm - NATlab commences pre-clinical validation

Batm Advanced CommunicationsAnnouncement

11/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241211:nRSK5870Pa&default-theme=true

RNS Number : 5870P  BATM Advanced Communications Ld  11 December 2024

LEI: 213800FLQUB9J289RU66

11 December 2024

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Key milestone achieved with commencement of NATlab pre-clinical validation

Latest phase begins at major Italian hospital following successful completion
of pre-clinical trials

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for
networking solutions and medical laboratory systems, is pleased to announce
that the NATlab molecular biology platform being developed by ADOR Diagnostics
("ADOR"), an associate company of the Group, has commenced pre-clinical
validation at the Lazzaro Spallanzani National Institute for Infectious
Diseases in Rome, Italy. This marks a key milestone in the development of
NATlab and, the Group believes, will enable initial sales as well as increase
industry awareness and interest from prospective partners.

 

The advanced NATlab molecular biology platform is a point-of-care
sample-to-answer solution designed to provide rapid and accurate diagnosis of
infectious disease. It uses a patented isothermal amplification method for
syndromic multiplex diagnostics to be able to rapidly identify a broad range
of pathogens from a single test.

 

The commencement of the pre-clinical validation phase follows the successful
completion of pre-clinical trials, which were conducted at the Tzafom Medical
Center in Israel, to confirm the validity of the biological process that ADOR
has developed and that it can be performed within the NATlab cartridge and
analyser device. NATlab identified all negative samples and had a 97%
sensitivity for the positive samples, confirming the efficacy of the system
and its ability to out-perform competing solutions available in the market
today because of its multiplex diagnostic capability for rapid and accurate
diagnosis.

 

ADOR has now made significant progress with NATlab with the full system
entering the pre-clinical validation phase at the Lazzaro Spallanzani National
Institute for Infectious Diseases in Rome, a leading centre for infectious
disease research and treatment. Successful completion of the pre-clinical
validation is expected to enable initial sales of the NATlab and the
commencement of the regulatory process under the European Union In Vitro
Diagnostic Medical Device Regulation to become eligible for sale in the EU
market.

 

In addition, following the success of the pre-clinical trials, ADOR, in
collaboration with the Tzafom Medical Center, has received a grant from the
Israel Innovation Authority to develop a NATlab panel for the diagnosis of
stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is
to be granted over two years based on the achievement of milestones.

 

Moti Nagar, Chief Executive Officer of BATM, said: "The commencement of the
pre-clinical validation phase at a major European hospital is an important
milestone in the development of NATlab and represents a key stage towards
enabling its market entry. This also follows the successful completion of
pre-clinical trials, which delivered excellent results. As the value of the
substantial IP that has been built within ADOR continues to increase as well
as the industry awareness of the attractiveness of the NATlab solution, we
remain excited about its prospects and look forward to reporting on further
progress."

 

 

Enquiries

 

 BATM
 Moti Nagar, Chief Executive Officer                            +972 9866 2525
 Ran Noy, Chief Financial Officer

 Shore Capital
 Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)  +44 20 7408 4050

 Gracechurch Group
 Harry Chathli, Claire Norbury                                  +44 20 4582 3500

 

Forward-looking statements

 

This document contains forward-looking statements. Those statements reflect
the current opinions, evaluations and estimations of the Group's management,
and are based on the current data regarding the Group's business as is
detailed in this document and in the Group's periodical, interim and immediate
reports. The Group does not undertake any obligation or make any
representation that actual results and events will be in line with those
statements, and stresses that they may differ materially from those
statements, due to changes in the Group's business, market, competition,
demand for the Group's products or services, general economic factors or other
factors that can influence the Group's business and results, due to the risk
factors that are detailed in the Group's Annual Report, and due to information
and factors that are currently unknown to the Group's management and that, if
known, would affect the management's opinions, evaluations or estimations. The
Group will report the actual results and events according to its legal,
accounting and regulatory obligations, and does not undertake any other
obligation to report them or their deviations from the forward-looking
statements, or to update any of the forward-looking statements in this
document or to report that it is not valid anymore.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGMGPUPCGBU